These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1607552)

  • 1. Venom immunotherapy: 10 years of experience with administration of single venoms and 50 micrograms maintenance doses.
    Reisman RE; Livingston A
    J Allergy Clin Immunol; 1992 Jun; 89(6):1189-95. PubMed ID: 1607552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stinging insect allergy: natural history and modification with venom immunotherapy.
    Reisman RE; Dvorin DJ; Randolph CC; Georgitis JW
    J Allergy Clin Immunol; 1985 Jun; 75(6):735-40. PubMed ID: 4008803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.
    van Halteren HK; van der Linden PW; Burgers JA; Bartelink AK
    J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 1):767-70. PubMed ID: 9438484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wasp venom is appropriate for immunotherapy of patients with allergic reaction to the European hornet sting.
    Kosnik M; Korosec P; Silar M; Music E; Erzen R
    Croat Med J; 2002 Feb; 43(1):25-7. PubMed ID: 11828554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients.
    Fricker M; Helbling A; Schwartz L; Müller U
    J Allergy Clin Immunol; 1997 Jul; 100(1):11-5. PubMed ID: 9257781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of venom immunotherapy: relationship to the severity of symptoms of initial insect sting anaphylaxis.
    Reisman RE
    J Allergy Clin Immunol; 1993 Dec; 92(6):831-6. PubMed ID: 8258617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of immunotherapy with venom in children with allergy to insect stings.
    Valentine MD; Schuberth KC; Kagey-Sobotka A; Graft DF; Kwiterovich KA; Szklo M; Lichtenstein LM
    N Engl J Med; 1990 Dec; 323(23):1601-3. PubMed ID: 2098016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.
    Birnbaum J; Charpin D; Vervloet D
    Clin Exp Allergy; 1993 Mar; 23(3):226-30. PubMed ID: 8472191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
    Müller U; Helbling A; Berchtold E
    J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy.
    Golden DB; Lawrence ID; Hamilton RH; Kagey-Sobotka A; Valentine MD; Lichtenstein LM
    J Allergy Clin Immunol; 1992 Sep; 90(3 Pt 1):386-93. PubMed ID: 1527321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis.
    van der Linden PW; Hack CE; Struyvenberg A; van der Zwan JK
    J Allergy Clin Immunol; 1994 Aug; 94(2 Pt 1):151-9. PubMed ID: 8064067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy.
    Blaauw PJ; Smithuis OL; Elbers AR
    J Allergy Clin Immunol; 1996 Jul; 98(1):39-47. PubMed ID: 8765816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy with commercial venoms is efficacious for anaphylactic reactions to Vespa orientalis stings.
    Goldberg A; Shefler I; Panasoff J; Paitan Y; Confino-Cohen R
    Int Arch Allergy Immunol; 2013; 161(2):174-80. PubMed ID: 23363701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan.
    Hirata H; Asakura T; Arima M; Cheng G; Honda K; Fukushima F; Yamaguchi B; Yoshida N; Fukuda T
    Asian Pac J Allergy Immunol; 2003 Jun; 21(2):89-94. PubMed ID: 14629126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
    Sturm G; Kränke B; Rudolph C; Aberer W
    J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Standardized rapid hyposensitization with purified hymenoptera venom in wasp venom allergy. Prospective study of development of tolerance and side-effect profile].
    Treudler R; Tebbe B; Orfanos CE
    Hautarzt; 1997 Oct; 48(10):734-9. PubMed ID: 9441166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom.
    Stritzke AI; Eng PA
    Clin Exp Allergy; 2013 Aug; 43(8):950-5. PubMed ID: 23889248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.